Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Faron

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Bulletin Du Cancer|August 12, 2023
[French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network]Christelle de la Fouchardière, Magalie Haissaguerre, Myriam Decaussin-Petrucci, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Impact of COVID-19 on healthcare organisation and cancer outcomesAurelie Bardet, Alderic M Fraslin, Jamila Marghadi, et al.
Cancer Medicine|August 16, 2022
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective studySarah Watson, Benjamin Verret, Stanislas Ropert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of <i>CTNNB1</i> Mutational StatusOlivier Mir, Charles Honoré, Ali N Chamseddine, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2022
Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patientsLambros Tselikas, Antoine Dardenne, Thierry de Baere, et al.
Endocrine-Related Cancer|August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC studyJulien Hadoux, Thomas Walter, Christina Kanaan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC NetworksSarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
The British Journal of Surgery|July 14, 2022
Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort studySébastien Gaujoux, Guillaume L Martin, Eric Mirallié, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2021
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN networkJulien Hadoux, Christina Kanaan, Alice Durand, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Bulletin Du Cancer|August 12, 2023
[French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network]Christelle de la Fouchardière, Magalie Haissaguerre, Myriam Decaussin-Petrucci, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Impact of COVID-19 on healthcare organisation and cancer outcomesAurelie Bardet, Alderic M Fraslin, Jamila Marghadi, et al.
Cancer Medicine|August 16, 2022
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective studySarah Watson, Benjamin Verret, Stanislas Ropert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of <i>CTNNB1</i> Mutational StatusOlivier Mir, Charles Honoré, Ali N Chamseddine, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2022
Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patientsLambros Tselikas, Antoine Dardenne, Thierry de Baere, et al.
Endocrine-Related Cancer|August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC studyJulien Hadoux, Thomas Walter, Christina Kanaan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC NetworksSarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
The British Journal of Surgery|July 14, 2022
Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort studySébastien Gaujoux, Guillaume L Martin, Eric Mirallié, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2021
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN networkJulien Hadoux, Christina Kanaan, Alice Durand, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Pageof 10